Events & Presentations

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Archives

Date Event Details
Dec 11, 2017
40th Annual San Antonio Breast Cancer Symposium - San Antonio, TX

Title:  Preclinical studies of RX-5902, a beta-catenin modulator in triple negative breast cancer   [View Poster]

Nov 15, 2017
8:00 AM ET
The Stifel 2017 Healthcare Conference
Sep 27, 2017
11:30 AM ET
The 2017 Disruptive Growth Company Showcase NYC
Sep 11, 2017
10:50 AM ET
The 19th Annual Rodman & Renshaw Global Investment Conference
Sep 8, 2017
2017 European Society for Medical Oncology (ESMO) Congress - Madrid, Spain

Title:   RX-3117, An Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Advanced Urothelial Cancer  [View Poster]

Title:  Phase 1 study of RX-5902, a novel Orally Bioavailable Inhibitor of Phosphorylated P68,which prevents β-catenin Translocation in Advanced Solid Tumors  [View Poster]

Title:  A Novel Small Molecule Nucleoside Analog, RX-3117, Shows Potent Therapeutic Activity in Combination with Nab-paclitaxel and Checkpoint Inhibitors in Xenograft Models  [View Poster]

 
Jun 2–6, 2017
American Society of Clinical Oncology (ASCO) 2017 Annual Meeting - Chicago, Illinois

Title: Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ib/IIa study [View Poster]

Feb 16, 2017
11:45 AM ET
2nd Annual Disruptive Growth & Healthcare Conference
Jan 19–21, 2017
ASCO Genitourinary Cancers Symposium - San Francisco, CA

Title: RX3117, An Oral Antimetabolite Nucleoside Shows Activity in Subjects with Pancreatic Cancer. Preliminary Results of Stage 1 of the Phase 1a/2b Study [View Poster]

Jan 10, 2017
8:30 AM PT
The 9th Annual Biotech Showcase™ 2017 conference
Oct 7–11, 2016
ESMO 2016 Congress From disease treatment to patient care

Title: RX-3117, An Oral Antimetabolite to Treat Advanced Solid Tumors (ST): Phase 1 and Ongoing Phase 2a Results

[View Poster]

Title: Phase 1/2a Study of RX-5902 in Advanced Solid Tumors (ST): an Orally Bioavailable Inhibitor of Phosphorylated p68 and Modulator of β-Catenin Nuclear Translocation

[View Poster]

Sep 12, 2016
11:15 AM ET
The 18th Annual Rodman & Renshaw Global Investment Conference
Jun 3–7, 2016
2016 American Society of Clinical Oncology Annual Meeting

Title: Results of a Phase 1 Study of Single Agent RX-3117, An Oral Metabolite Nucleoside to Treat Solid Tumors.
[View Poster]

Title: Results of a Phase 1 Study of RX-5902, An Orally Available Inhibitor of Phosphorylated P68, Targeting Solid Tumors.

[View Poster]

Title: Results from a Phase 1b/2 Study of RX-0201, A Novel AKT-1 Antisense, Combined with Everolimus to Treat Metastatic Clear Cell Renal Carcinoma.
[View Poster]

Apr 16–20, 2016
American Association for Cancer Research (AACR) 107th Annual Meeting

Title: Phase Ib/II Study of RX-0201, a Novel AKT-1 Antisense Combined with Everolimus to Treat Metastatic Renal Cell Carcinoma – Phase Ib Results.
[View Poster]

Title: Folate Receptor-Targeted Lipid Coated Albumin Nanoparticles (F-LCAN) for Therapeutic Delivery of RX-0201 (Archexin®), an Antisense Oligonucleotide Against AKT-1.
[View Poster]

Title: Inhibition of DNA Methyltransferase by RX-3117 Leads to Upregulation of Hypomethylated Targets.
[View Poster]

 

Mar 21–23, 2016
14th Annual Targeted Anticancer Therapeutics Congress (TAT 2016)
Location: Washington, DC

Title: Novel Targeted Phosphorylated p68 Inhibitor RX-5902 Shows Activity in Triple-Negative Breast Cancer Presentation .
[View Presentation]

Feb 8–9, 2016
18th Annual BIO CEO Investor Conference
Location: New York, NY
Jan 21–23, 2016
ASCO Gastrointestinal Cancers Symposium

Title: RX-5902 a Phosphorylated p68 Targeting Agent to Treat Subjects with Advanced Solid Tumors.
[View Poster]

Title: The Anticancer Effects of Supinoxin (RX-5902) in Pancreatic Cancer.
[View Poster]

Jan 11, 2016
4:30 PM PT
8th Annual Biotech Showcase Investor Conference 2016
Location: San Francisco, CA
Jan 7–9, 2016
ASCO Genitourinary Cancers Symposium
Location: San Francisco, CA

Title: Archexin, A Novel AKT-1 Specific Inhibitor for the Treatment of Metastatic Renal Cancer – Preliminary Stage 1 Data.
[View Poster]

Title: The Anticancer Effects of Supinoxin(RX-5902) in Renal Cell Cancer.
[View Poster]

Dec 8–10, 2015
The 38th Annual San Antonio Breast Cancer Symposium
Location: San Antonio, Texas

Title: New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer.
[View Poster]

Nov 17–18, 2015
Stifel 2015 Healthcare Conference
Location: New York, NY
Nov 6–7, 2015
14th Annual Kidney Cancer Symposium
Location: Miami, FL

Title: RX-0201, An Anti-Sense Targeting AKT-1 to Treat Metastatic Renal Cancer - Preliminary Stage 1 Data.
[View Poster]

Oct 20, 2015
2:30 PM PT
14th Annual BIO Investor Forum
Location: San Francisco, CA
Sep 27, 2015
The 18th ECCO – 40th ESMO European Cancer Congress 2015

Title: Single Agent Supinoxin Targeting Phosphorylated p-68, Preliminary Phase I Data.
[View Poster]

Title: Preliminary Phase I Data of Single Agent RX-3117, an Oral Antimetabolite Nucleoside.

[View Poster]

Sep 16, 2015
1:45 PM ET
The BioPharm America™ 2015 Conference
Sep 10, 2015
11:40 AM ET
17th Annual Rodman & Renshaw Global Investment Conference
Location: New York, NY
May 29–Jun 2, 2015
The 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Title: A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors.
[View Poster]

Title: A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors.
[View Poster]

Title: A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma.
 [View Poster]

Title: A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors.
[View Abstract]

Apr 18–22, 2015
American Association for Cancer Research (AACR) 106th Annual Meeting

Title: Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker
 [View Poster]

Title: Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)
 [View Poster]

 

Mar 9, 2015
ROTH Capital Partners 27th Annual Growth Stock Conference
Feb 10, 2015
2015 BIO CEO & Investor Conference
Jan 14, 2015
The Seventh Annual Biotech Showcase™ Investor Conference
Dec 10, 2014
Oppenheimer & Co. Inc. 25th Annual Healthcare Conference
Nov 18, 2014
The Stifel 2014 Healthcare Conference
Oct 7, 2014
The 13th Annual BIO Investor Forum
Sep 9, 2014
The 16th Annual Rodman & Renshaw Global Investment Conference
Apr 5–9, 2014
American Association for Cancer Research (AACR) 105th Annual Meeting

Title: A novel small molecule cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to treatment with gemcitabine
 [View Poster]

Title: Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy
 [View Poster]

 

Mar 11, 2014
The 26th Annual ROTH Conference
Feb 10, 2014
Rexahn Pharmaceuticals presentation from the 2014 BIO CEO & Investor Conference
Jan 14, 2014
Rexahn Pharmaceuticals at Biotech Showcase 2014
Sep 9, 2013
Rodman & Renshaw Annual Global Investment Conference
Apr 22–25, 2013
2013 BIO International Convention in Chicago, Illinois
Apr 6–10, 2013
American Association for Cancer Research (AACR) 104th Annual Meeting

Title: Mechanistic study of a new 4-(3, 5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902)
 [View Poster]

Mar 17–20, 2013
25th Annual ROTH Conference at the Ritz-Carlton, Laguna Niguel in Dana Point, CA.
Add to Briefcase = add file to Briefcase


©2017 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy